CL2013003137A1 - Oral liquid pharmaceutical composition containing divalproex sodium (2-15% w / v of the composition), and one or more excipients, whose ph is greater than 6; method of preparing the composition comprising: (a) mixing sodium hydroxide in purified water, (b) adding sodium divalproex and excipients; and (c) adjust ph over 6. - Google Patents

Oral liquid pharmaceutical composition containing divalproex sodium (2-15% w / v of the composition), and one or more excipients, whose ph is greater than 6; method of preparing the composition comprising: (a) mixing sodium hydroxide in purified water, (b) adding sodium divalproex and excipients; and (c) adjust ph over 6.

Info

Publication number
CL2013003137A1
CL2013003137A1 CL2013003137A CL2013003137A CL2013003137A1 CL 2013003137 A1 CL2013003137 A1 CL 2013003137A1 CL 2013003137 A CL2013003137 A CL 2013003137A CL 2013003137 A CL2013003137 A CL 2013003137A CL 2013003137 A1 CL2013003137 A1 CL 2013003137A1
Authority
CL
Chile
Prior art keywords
excipients
composition
divalproex
sodium
preparing
Prior art date
Application number
CL2013003137A
Other languages
Spanish (es)
Inventor
Dipak Sahana
Prasad Patil
Ganesh Narayan Phadtare
Manish Grover
Shripad Jathar
Original Assignee
Abbott Healthcare Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46939730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Healthcare Private Ltd filed Critical Abbott Healthcare Private Ltd
Publication of CL2013003137A1 publication Critical patent/CL2013003137A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Abstract

La solicitud 201303137 describe a una composición farmacéutica líquida oral que comprende divalproex sódico y uno o más excipientes farmacéuticamente aceptables donde el pH de la composición es mayor a 6; y un procedimiento para su preparación que da cuenta de las etapas de (a) preparar la disolución de hidróxido de sodio en agua purificada; (b) disolver divalproex sódico y uno o más excipientes farmacéuticamente aceptables con agitación en la solución del paso (a), hasta que cada ingrediente esté disuelto; y (c) ajustar el pH de la disolución del paso (b) a un pH mayor a 6.Application 201303137 describes an oral liquid pharmaceutical composition comprising divalproex sodium and one or more pharmaceutically acceptable excipients where the pH of the composition is greater than 6; and a process for its preparation that accounts for the steps of (a) preparing the solution of sodium hydroxide in purified water; (b) dissolve divalproex sodium and one or more pharmaceutically acceptable excipients with stirring in the solution of step (a), until each ingredient is dissolved; and (c) adjust the pH of the solution of step (b) to a pH greater than 6.

CL2013003137A 2011-05-02 2013-10-30 Oral liquid pharmaceutical composition containing divalproex sodium (2-15% w / v of the composition), and one or more excipients, whose ph is greater than 6; method of preparing the composition comprising: (a) mixing sodium hydroxide in purified water, (b) adding sodium divalproex and excipients; and (c) adjust ph over 6. CL2013003137A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1365MU2011 2011-05-02

Publications (1)

Publication Number Publication Date
CL2013003137A1 true CL2013003137A1 (en) 2014-08-01

Family

ID=46939730

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003137A CL2013003137A1 (en) 2011-05-02 2013-10-30 Oral liquid pharmaceutical composition containing divalproex sodium (2-15% w / v of the composition), and one or more excipients, whose ph is greater than 6; method of preparing the composition comprising: (a) mixing sodium hydroxide in purified water, (b) adding sodium divalproex and excipients; and (c) adjust ph over 6.

Country Status (6)

Country Link
BR (1) BR112013027685A2 (en)
CL (1) CL2013003137A1 (en)
CO (1) CO6801771A2 (en)
EC (1) ECSP13013043A (en)
MX (1) MX2013012827A (en)
WO (1) WO2012150607A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104248627A (en) * 2013-06-25 2014-12-31 北大方正集团有限公司 Valproate semisodium-containing effervescent dry suspension and preparation method thereof
BE1026024B1 (en) * 2018-02-16 2019-09-16 Neogen Nv Method for preparing a solution comprising valproic acid and / or one or more of its salts, said solution and use
CN114760976A (en) 2019-12-16 2022-07-15 高露洁-棕榄公司 Oral care composition containing inulin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
FR2643556B1 (en) 1989-02-27 1993-03-05 Sanofi Sa PHARMACEUTICAL COMPOSITION WITH SUSTAINED RELEASE OF VALPROIC ACID
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
US20110015267A1 (en) * 2009-07-20 2011-01-20 Deanna Jean Nelson Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine

Also Published As

Publication number Publication date
BR112013027685A2 (en) 2016-12-27
WO2012150607A2 (en) 2012-11-08
CO6801771A2 (en) 2013-11-29
MX2013012827A (en) 2014-02-11
WO2012150607A3 (en) 2013-02-14
ECSP13013043A (en) 2014-01-31

Similar Documents

Publication Publication Date Title
BR112016010383A2 (en) selective pyy compounds and uses thereof
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
UA106636C2 (en) MORPHOLINOTIAZOLES AS A POSITIVE ALLOSTERIC ALPHA MODULATORS 7
EA201690069A1 (en) THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE
BR112014024833A8 (en) VETERINARY SOFT CHEWABLE PHARMACEUTICAL PRODUCT, PROCESS FOR MANUFACTURING A PRODUCT, USE OF PAMOIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE OF A SOFT CHEWABLE VETERINARY PHARMACEUTICAL COMPOSITION, AND, SOFT CHEWABLE VETERINARY PHARMACEUTICAL COMPOSITION.
ECSP12011838A (en) CHROMENONE DERIVATIVES WITH ANTI-TUMORAL ACTIVITY
PE20120713A1 (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS FOR ITS USE
CL2004000899A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING TELMISARTAN SODIUM SALT AND A DIURETIC AGENT AND PREPARATION PROCEDURE.
BR112014001083B8 (en) Compound, process for preparing a compound, pharmaceutical composition, use of the pharmaceutical composition and use of the compound
CL2011002807A1 (en) Compressible pharmaceutical mixture comprising crystals of a drug with a particle size of less than 40 um and a dissolution aid; A method of preparing a delivery vehicle for a drug that includes grinding a premix of drug crystals and a dissolution aid.
NO20084478L (en) Conjugated Lipid Derivatives
EA201690005A1 (en) COMPOSITION WITH MODIFIED EXTRUSION KINETICS
CL2013003137A1 (en) Oral liquid pharmaceutical composition containing divalproex sodium (2-15% w / v of the composition), and one or more excipients, whose ph is greater than 6; method of preparing the composition comprising: (a) mixing sodium hydroxide in purified water, (b) adding sodium divalproex and excipients; and (c) adjust ph over 6.
AR089122A1 (en) ORAL FORMULATIONS TO TREAT METAL OVERLOAD
CL2016002318A1 (en) Pharmaceutical composition in the form of a solution comprising a liquid carrier comprising water and between 20% and 95% of one or more alcohols and sildenafil citrate dissolved in said liquid carrier at a concentration of between 7 and 125 mg / ml; methods to obtain it; oral dosage form; oral dosage form; kits
CO7170181A2 (en) New composition of alfentanil for the treatment of acute pain
EA201992382A2 (en) ORAL TABLET PHARMACEUTICAL COMPOSITION FOR DOUBLE USE ON THE BASIS OF SULPHATE SALTS AND METHODS OF ITS APPLICATION
EA201490573A1 (en) CONTAINING BENZOTHIAZOLONE
AR087371A1 (en) FORMULATIONS OF (TRIMETOXIFENILAMINO) PYRIMIDINYL, METHODS
AR086491A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING FEXOFENADINE
BR112016021471A8 (en) Azaindole acetic acid derivatives and their use as prosrtglandin d2 receptor modulators
BR112015018200A2 (en) chewable composition for oral administration and process for preparing same
MX2017015202A (en) Liquid formulations of celecoxib for oral administration.
BR112013029790A2 (en) pharmaceutical composition comprising ketoprofen
EA201391512A1 (en) SOLID PHARMACEUTICAL COMPOSITION